Thammathiwat T.Chompuk L.Worawichawong S.Boonpucknavig V.Sirilak S.Pongcharoen S.Pichitsiri W.Kanjanabuch T.Mahidol University2023-05-192023-05-192023-01-01Vaccines Vol.11 No.1 (2023)https://repository.li.mahidol.ac.th/handle/20.500.14594/81972Vaccination against the SARS-CoV-2 virus (COVID-19) has proven to be the most effective measure to prevent the spread and reduce infection severity. A case report of de novo membranous nephropathy (MN) following immunization with inactivated virus vaccine (CoronaVac®, Sinovac Biotech) is presented here. A 53-year-old man presented with a sudden onset of leg edema a week after receiving an inactivated virus vaccine and a relapse of nephrotic syndrome (NS) with acute kidney injury (AKI) after a booster dose. Screening for serum anti-phospholipase A2 receptor antibody and secondary causes of MN were negative. Kidney biopsy revealed an early MN pattern with focal spike formation, whilst numerous subepithelial electron-dense deposits and a few small deposits in the mesangial area were observed through electron microscopy. A short course of steroids and oral cyclophosphamide was prescribed, resulting in the complete remission of NS and AKI. MN following SARS-CoV-2 vaccination should call for medical importance. Awareness of the association between vaccination and MN should be kept in mind to avoid unnecessary treatment with long-term immunosuppressive agents.Immunology and MicrobiologyArticleSCOPUS10.3390/vaccines110100802-s2.0-851467797622076393X